Shots: The approval is based on P-III study including 2 phases assessing tofacitinib (5mg or 1mg/mL oral solution, bid) for 44wks. The 2phases includes an 18 wks. open-label, run-in phase […]readmore
Tags : Active Polyarticular Course Juvenile Idiopathic Arthritis